Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10985213 | 0.77 | LMNA (0.58) | ALDH1A1HDAC6 | |
| SCHEMBL25199807 | 0.77 | DDR1 (0.51) | EGLN1MMP13 | |
| SCHEMBL5926497 | 0.76 | KDM4C (0.56) | KMOALDH1A1 | |
| SCHEMBL5926838 | 0.75 | CTSA (0.59) | MMP13 | |
| SCHEMBL5926832 | 0.73 | KIFC1 (0.66) | ITGB3ITGA2B | |
| SCHEMBL5214415 | 0.73 | NAMPT (0.54) | MMP13ALDH1A1 | |
| SCHEMBL12999520 | 0.72 | ITGB3 (0.61) | EGLN1ITGB3ITGA2BALDH1A1 | |
| SCHEMBL15104584 | 0.71 | CTSA (0.51) | ALDH1A1 | |
| SCHEMBL10992192 | 0.71 | EGLN1 (0.56) | EGLN1ALDH1A1 | |
| SCHEMBL16093766 | 0.70 | ALDH1A1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | GCGR 663/4885EGLN1 872/4885KMO 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.